Stock Market Reviews

ALLR (Allarity Therapeutics, Inc.) News

Get the latest news, insights, and market updates on ALLR (Allarity Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
  Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung CancerTrial is fully funded by the U.S. Department of Veterans Affairs and is open for enrollment at 11 VA sites nationwide Relapsed SCLC remains an area of high unmet need without effective treatment options TARPON SPRINGS, Fla., February 18, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to develo
  Feb 18, 2026 - $ALLR
• Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
  This is the first trial combining Allarity’s stenoparib with another anti-cancer agent Stenoparib’s favorable safety profile supports potential for use in combination regimens Trial is fully funded by the U.S. Department of Veterans Affairs and is open to enrollment at 11 VA sites throughout the US TARPON SPRINGS, Fla., February 3, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2
  Feb 3, 2026 - $ALLR
• Allarity CEO says 2026 represents an ‘inflection point’
  Allarity (ALLR) Therapeutics issued a letter to shareholders from the Company’s CEO, which read, in part, “As we close out 2025, I write to you with both optimism and gratitude. Your continued support has helped steer Allarity Therapeutics through a period of meaningful transformation and disciplined execution. This December marks two years since I assumed the role of CEO. Since that time, our efforts have been anchored by a clear and focused strategy centered on advancing stenoparib, our novel
  Jan 1, 2026 - $ALLR
• Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
  TARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today issued the following letter to shareholders from the Company’s Chief Executive Officer.Dear Shareholders, As we close out 2025, I write to you with both optimism and gratitude. Your continued support has helped steer Allarity Therap
  Dec 31, 2025 - $ALLR
• Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
  Received FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding 25 months in ongoing Phase 2 trialAdvanced DRP® platform through new licensing agreement TARPON SPRINGS, Fla., November 14, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today reported
  Nov 14, 2025 - $ALLR
• Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
  - Kaplan-Meier analyses show for the first time that median Overall Survival exceeds 25 months for Platinum Resistant and Refractory Ovarian Cancer Patients receiving stenoparib/2X-121 twice daily - Two patients continue on therapy now more than 24 months - Clinical Benefit Evident in patients with BRCAwt as well as BRCAmut genetics - Data presented at the American Association for Cancer Research (AACR) 7th Biennial Special Conference on Ovarian Cancer, Denver CO TARPON SPRINGS, Fla., September
  Sep 22, 2025 - $ALLR
• Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
  TARPON SPRINGS, Fla., September 17, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced that its CEO, Thomas Jensen, has been invited to present at the upcoming Biomarkers & Precision Medicine 2025 conference in London, organized by Oxford Global. In addition to his presentation, Mr. Jensen will be interviewed by Oxf
  Sep 17, 2025 - $ALLR
• Sector Update: Health Care Stocks Higher Late Afternoon
  Health care stocks advanced late Tuesday afternoon with the NYSE Health Care Index rising 0.6% and t
  Aug 26, 2025 - $ALLR
• BC-Most Active Stocks
  Raytech Holding Ltd. 21,549,901 3.68
  Aug 26, 2025 - $ALLR
• Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
  TARPON SPRINGS, Fla., August 26, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to stenoparib, its investigational treatment for patients with advanced ovarian cancer. The FDA’s Fast Track designation is intended to expedite the
  Aug 26, 2025 - $ALLR